Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 78 results for "arun sawhney"

Despite HC directions, deptts reluctant to provide informatio...

* Many erring officials enjoy prime postings Mohinder Verma JAMMU, Apr 22: Notwithstanding explicit directions from the High Court and numerous reminders from the General Administration Department, 21 Government departments are reluctant to ... Daily, 9 hours ago

3 images for "arun sawhney", 2 weeks ago, 2 months ago
The Hindu, 5 months ago

Industry experts hopeful of quick market revival

The Indian auto market has a bright future in spite of the unprecedentedly prolonged phase of recession being currently witnessed. This was the message that emerged in no uncertain terms from the deliberations at Auto Summit 2014 held in New Delhi ...
 MotorIndia1 day ago

The Law of Gravity Isn't Working for This Off-Patent Drug

In the drug business, the arrival of generic competition usually means falling prices as rivals rush to win market share for medicines whose patents have expired. Then there's Diovan from Novartis This patent-law quirk has expensive consequences ...
 BusinessWeek5 days ago Heart Drug Costs $900 Million More as Generic Held Back: Health  Washington Post1 week ago Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs  Bloomberg1 week ago Ranbaxy's woes add $900 million in costs for heart drug  Livemint.com1 week ago
Business Standard India

Ranbaxy may have to pay huge fine, again

Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility is currently banned from supplying products ...
 Business Standard India1 week ago

India's Sun Pharma Takes Over a Beleaguered Ranbaxy Labs

Indian pharmaceutical firm Ranbaxy Laboratories has struggled ever since its promoter family sold controlling interest in the company to Japan's Daiichi Sankyo in 2008. No one, however, expected the Japanese pharma major to give up the fight. In an ...
 Wharton1 week ago Sun Pharma buys Ranbaxy for $3.2b, turns it Indian again  The Financial Chronicle2 weeks ago Sun Pharma buys Ranbaxy to create generics giant  Livemint.com2 weeks ago Sun Pharma to buy Ranbaxy in $3.2B all-stock deal  VC Circle2 weeks ago
Business Standard India

DAIICHI SANKYO : Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo's Subsidiary Ranbaxy and Resulting Change in Subsidiary

For Immediate Release 2014.04.11 Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate ...
 4 Traders1 week ago Ranbaxy: Lessons and Opportunities  PharmaceuticalProcessing1 week ago Top heads to roll soon at Ranbaxy  Business Standard India1 week ago Sun Pharma to acquire Ranbaxy  The Hindu2 weeks ago

Dilip Shanghvi | The Dealmaker

Mumbai: On hindsight, which is always 20:20, the stock movement in the preceding week should have foretold the story. On Friday, 4 April, shares of Ranbaxy Laboratories Ltd rose 8.2% to Rs. 459.55 on BSE, taking the stock's weekly gain to 26%. ...
 Livemint.com1 week ago

Ranbaxy's TL Easwar of API quits post introspection

NEW DELHI: A senior-level exit has taken place at Ranbaxy Laboratories, after Chairman Tsutomu Une, a veteran at Japanese parent Daiichi Sankyo, held an open house meeting to introspect on what went wrong with the company and who should be held ...
 Economic Times2 weeks ago Ranbaxy's TL Easwar quits post introspection  Economic Times2 weeks ago
Business Standard India

A look at Ranbaxy's chequered legacy

The move is seen as enhancing the company's global presence Sushmi Dey | New Delhi April 8, 2014 Last Updated at 00:25 IST Sun Pharma’s acquisition of Ranbaxy has once again revived evaluation of the troubled past of the latter, which had ...
 Business Standard India2 weeks ago

Challenges for Sun Pharma post Ranbaxy deal

T 1: Achieving Compliance With the baggage of regulatory issues, the biggest challenge for Sun Pharma will be to restore and regain trust and confidence of the regulators, especially in the US. Four of Ranbaxy plants are banned by USFDA and is ...
 Moneycontrol.com2 weeks ago 5 challenges for Sun in Ranbaxy deal | Shanghvi, pharma maven with midas touch  Economic Times2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - arun sawhney
Get updated on latest news & your favorite topics right in your inbox!
More     Less